Institution identification

Institution ID

50258

Institution full name and acronym

Parexel International

Institution countries

United States

Type of institution

Non-Pharmaceutical company

Institution website

ENCePP partner

Yes
Institution description
PAREXEL, a leading global biopharmaceutical services provider operating 70 locations throughout 54 countries, has a team of clinical research experts providing strategic and scientific solutions to facilitate the transition from development to commercialization. Working with biopharmaceutical companies as well as government-based and academic organizations, these experts profile product safety in real-world settings, provide evidence of product value and effectiveness, and conduct trials to extend the product lifecycle. PAREXEL has significant expertise in post-licensing, ranging from risk management, regulatory consulting, and pharmacoepidemiology to health outcomes. The company has implemented some of the largest, most complex trials of marketed products ever conducted.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

A MULTICENTER, MULTICOUNTRY, POSTMARKETING ACTIVE SURVEILLANCE TALIGLUCERASE ALFA REGISTRY IN PATIENTS WITH GAUCHER DISEASE
A non-interventional post-authorisation safety study to investigate drug utilisation and safety monitoring patterns for Lemtrada (alemtuzumab)
A non-interventional post-authorisation safety study to investigate the risk of mortality in multiple sclerosis patients treated with alemtuzumab (LEMTRADA®) relative to comparable multiple sclerosis patients using other disease modifying therapies: a cohort study
A Phase IV Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated with AZD1222
CONTOUR Australia: Condition of Submental Fullness and Treatment
CONTOUR: Condition of Submental Fullness and Treatment Outcomes Registry (A Registry of Submental Fullness, Treatment Options Administered, and Associated Outcomes)
Descriptive Study of the Incidence of Malignancy in Patients with Severe Asthma Overall and Among Those Receiving Benralizumab and Other Therapies, a Post Authorization Safety Study
Drug utilisation study of Eliglustat for the treatment of Gaucher Disease Type 1 in Europe using electronic healthcare records (ELIGLC06913)
LONG-TERM SURVEILLANCE STUDY OF LATANOPROST TO MONITOR HYPERPIGMENTATION CHANGES IN THE EYE IN PEDIATRIC POPULATIONS
Post-authorisation safety study (PASS) to evaluate risk minimisation measures for medication errors with Uptravi during the titration phase in patients with pulmonary arterial hypertension (PAH) in clinical practice (EDUCATE)
REACH study: Real-World Evidence study of OM-85 in Adults and Children in China, Italy, and Belgium